The therapeutic effectiveness of eculizumab in atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) was measured using special assays that track eculizumab trough levels and CH 50 activity with established thresholds in these conditions. Here, C4B is linked to atypical hemolytic-uremic syndrome.